We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Screening Test Detects Chlamydial Infection

By LabMedica International staff writers
Posted on 26 Mar 2013
A rapid nonculture method for detection of Chlamydia trachomatis has been developed based on the measurement of specific enzymatic activity in urogenital tract specimens.

The method is based on the level of the activity of α-mannosidase, a gylcoside hydrolase involved in the maturation and degradation of glycoprotein-linked oligosaccharides, on its specific chromogen. More...


Scientists at Zhengzhou University (China) evaluated the performance of a method, which measured the α-mannosidase activities of C. trachomatis serotype D strain and 29 standard strains related to clinical urogenital pathogens. They also assayed 553 urogenital tract specimens via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.

For the 203 male cases, three urethral discharge specimens from 151 outpatients or three prostate massage liquid specimens from 52 outpatients were collected with sterile rayon swabs. For the 350 female cases, three cervical secretion specimens were collected from 232 outpatients, or three vaginal secretion specimens were collected from 118 outpatients, with sterile rayon swabs using vaginal forceps.

The enzymatic method was based on the substrate 6-chloro-3-indolyl-α-D-mannoside and the chromogenic reagent contained fast violet B salt (J&K Chemical; Shanghai, China; www.jkchemical.com). The result was considered to be positive when the optical density (OD) at 512 nm was greater than 0.150, if the color changed from colorless to red or brown after 15 minutes of incubation at 37 °C. Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method.

Of the 553 clinical samples, 132 samples were positive with the OD ranging from 0.161 to 1.955, and 421 samples were negative with OD ranging from 0.013 to 0.142. The sensitivity of the enzymatic method was 91.5%, and the specificity of this method was 90.0%.

The authors concluded that they had demonstrated that there were no significant differences between the enzymatic method and the reference method if prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and specialized equipment is not essential. The study was published on January 24, 2013, in, the BioMed Central journal BMC Infectious Diseases.

Related Links:

Zhengzhou University
J&K Chemical



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.